Comparing Colorectal Cancer Screening Test Performance

In ‘Comparing Colorectal Cancer Screening Test Performance,’ our panel explores the performance and practical considerations of available colorectal cancer (CRC) screening modalities, highlighting how test accuracy, frequency, and patient preference influence clinical decision-making. Colonoscopy remains the gold standard, offering high sensitivity (typically around 95%) and the advantage of both detection and intervention. However, it is not without limitations, including variability in preparation quality and patient tolerance.

The panelists discuss alternative modalities, such as CT colonography, stool-based tests, and emerging blood-based assays, which provide additional options with varying levels of sensitivity and invasiveness. Stool-based tests, including fecal immunochemical testing (FIT) and multitarget stool DNA tests, offer noninvasive approaches with sensitivities that vary by method, while blood-based tests demonstrate moderate sensitivity and are gaining attention as convenient screening tools.

The discussion emphasizes that no single test is perfect, and clinicians must balance test performance with factors such as screening intervals, patient adherence, and individual preferences. For example, while colonoscopy may be performed every 10 years, stool-based tests require more frequent repetition, and CT colonography is typically recommended every 5 years. The segment reinforces the importance of shared decision-making, ensuring patients understand the benefits and limitations of each option to make informed screening choices.

Our next episode, ‘Comparing CRC-specific and Multi-Cancer Blood Tests,’ the panelists discuss how MCED blood tests offer broad cancer detection but have lower sensitivity for colorectal cancer and should not replace guideline-recommended CRC-specific screening. Clinicians play a critical role in helping patients understand these differences and make informed screening decisions.